Determinants of Extracellular Matrix Remodelling are Differentially Expressed in Paediatric and Adult Dilated Cardiomyopathy
Open Access
- 1 March 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 13 (3) , 271-277
Abstract
Aims The left ventricular phenotype of idiopathic dilated cardiomyopathy (DCM) can appear similar in paediatric and adult patients. However, the aetiology of paediatric DCM is usually idiopathic, and often leads an aggressive clinical course. A structural underpinning of DCM is extracellular matrix changes, which are determined by a balance between matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs). This study tested the hypothesis that different MMP/TIMP profiles occur in paediatric and adult DCM patients. Methods and results Left ventricular samples from paediatric (age 9 ± 5 years; n = 10) and adult (age 62 ± 3 years; n = 20) DCM (at time of transplant) were subjected to an MMP/TIMP multiplex array and immunoassay in order to measure the MMP subclasses; collagenases (MMP−8, −13), gelatinases (MMP−2, −9), stromelysin/matrilysin (MMP−3, −7), membrane type (MT1‐MMP), as well as for the four known TIMPs. MMP−8 and −9 levels increased by over 150% (P < 0.05), whereas MMP−3 and −7 levels decreased by over 30% (P < 0.05) in paediatric DCM when compared with adult DCM. TIMP−1 and −2 levels increased two‐fold (P < 0.05), but TIMP‐3 fell by 41% (P < 0.05) in paediatric DCM. Myocardial levels of specific interleukins (IL‐1beta, IL‐2, IL‐8) were increased by approximately 50% in paediatric DCM. Conclusions These unique findings demonstrated that a specific MMP/TIMP profile occurs in paediatric DCM when compared with adult DCM, and that local cytokine induction may contribute to this process. These distinct differences in the determinants of myocardial matrix structure and function may contribute to the natural history of DCM in children.Keywords
This publication has 33 references indexed in Scilit:
- TIMPs and cardiac remodeling: ‘Embracing the MMP-independent-side of the family’Journal of Molecular and Cellular Cardiology, 2010
- Predictors of Outcome in Patients With Suspected MyocarditisCirculation, 2008
- Differential Effects of Epsilon-aminocaproic Acid and Aprotinin on Matrix Metalloproteinase Release in Patients Following Cardiopulmonary BypassJournal of Cardiovascular Pharmacology, 2008
- Tissue Inhibitor of Metalloproteinases-4. The road less traveledMolecular Cancer, 2008
- Membrane-type-1 matrix metalloproteinase transcription and translation in myocardial fibroblasts from patients with normal left ventricular function and from patients with cardiomyopathyAmerican Journal of Physiology-Cell Physiology, 2007
- Specific Temporal Profile of Matrix Metalloproteinase Release Occurs in Patients After Myocardial InfarctionCirculation, 2006
- Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcomeCardiovascular Research, 2006
- Comparison of Levels of Matrix Metalloproteinase-2 and -3 in Patients With Ischemic Cardiomyopathy Versus Nonischemic CardiomyopathyThe American Journal of Cardiology, 2005
- Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblastsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosisThe American Journal of Cardiology, 1995